CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 290 enrolled
Drug / intervention
ALT-BB4 +1 moredrug
Likely dose
0.9%NaClfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05232175
NCT05232175Phase 1Completed
CompareCT.gov

A Phase I Study to Evaluate the Tolerance, Safety and Pharmacokinetics of ALT-BB4 in Healthy Volunteer

Alteogen, Inc.·interventional·Posted Feb 9, 2022·Updated Jan 29, 2026

In Brief

A Phase 1 clinical trial evaluating ALT-BB4 and 0.9%NaCl for Health, Subjective. Completed, enrolled 290 participants across 1 site.

Detailed Summary

A Phase I Study to Evaluate the Tolerance, Safety and Pharmacokinetics of ALT-BB4 in Healthy Volunteers

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealth, Subjective
CountriesSouth Korea
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedFeb 9, 2022
Enrollment StartJan 18, 2022
Primary CompletionAug 24, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.4 years ago

Interventions

ALT-BB4drug

Recombinant Hyaluronidase

0.9%NaCldrug

Normal Saline